Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 692

1.

Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial.

Croop R, Goadsby PJ, Stock DA, Conway CM, Forshaw M, Stock EG, Coric V, Lipton RB.

Lancet. 2019 Jul 12. pii: S0140-6736(19)31606-X. doi: 10.1016/S0140-6736(19)31606-X. [Epub ahead of print]

PMID:
31311674
2.

Rimegepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, for Migraine.

Lipton RB, Croop R, Stock EG, Stock DA, Morris BA, Frost M, Dubowchik GM, Conway CM, Coric V, Goadsby PJ.

N Engl J Med. 2019 Jul 11;381(2):142-149. doi: 10.1056/NEJMoa1811090.

PMID:
31291516
3.

Trial of Galcanezumab in Prevention of Episodic Cluster Headache.

Goadsby PJ, Dodick DW, Leone M, Bardos JN, Oakes TM, Millen BA, Zhou C, Dowsett SA, Aurora SK, Ahn AH, Yang JY, Conley RR, Martinez JM.

N Engl J Med. 2019 Jul 11;381(2):132-141. doi: 10.1056/NEJMoa1813440.

PMID:
31291515
4.

Targeting CGRP and 5-HT1F Receptors for the Acute Therapy of Migraine: A Literature Review.

Moreno-Ajona D, Chan C, Villar-Martínez MD, Goadsby PJ.

Headache. 2019 Jul;59 Suppl 2:3-19. doi: 10.1111/head.13582. Review.

PMID:
31291016
5.

Managing cluster headache.

Wei DY, Khalil M, Goadsby PJ.

Pract Neurol. 2019 Jul 5. pii: practneurol-2018-002124. doi: 10.1136/practneurol-2018-002124. [Epub ahead of print]

6.

Differential efficacy of non-invasive vagus nerve stimulation for the acute treatment of episodic and chronic cluster headache: A meta-analysis.

de Coo IF, Marin JC, Silberstein SD, Friedman DI, Gaul C, McClure CK, Tyagi A, Liebler E, Tepper SJ, Ferrari MD, Goadsby PJ.

Cephalalgia. 2019 Jul;39(8):967-977. doi: 10.1177/0333102419856607. Epub 2019 Jun 10.

PMID:
31246132
7.

Eptinezumab for prevention of chronic migraine: A randomized phase 2b clinical trial.

Dodick DW, Lipton RB, Silberstein S, Goadsby PJ, Biondi D, Hirman J, Cady R, Smith J.

Cephalalgia. 2019 Aug;39(9):1075-1085. doi: 10.1177/0333102419858355. Epub 2019 Jun 24.

PMID:
31234642
8.

The Association Between Parental Migraine and Infant Colic: A Cross-Sectional, Web-Based, U.S. Survey Study.

Gelfand AA, Buse DC, Cabana MD, Grimes B, Goadsby PJ, Allen IE.

Headache. 2019 Jul;59(7):988-1001. doi: 10.1111/head.13575. Epub 2019 Jun 20.

PMID:
31222745
9.

Trigeminal autonomic cephalalgias presenting in a multidisciplinary tertiary orofacial pain clinic.

Wei DY, Moreno-Ajona D, Renton T, Goadsby PJ.

J Headache Pain. 2019 Jun 11;20(1):69. doi: 10.1186/s10194-019-1019-7.

10.

Long-term safety and tolerability of erenumab: Three-plus year results from a five-year open-label extension study in episodic migraine.

Ashina M, Goadsby PJ, Reuter U, Silberstein S, Dodick D, Rippon GA, Klatt J, Xue F, Chia V, Zhang F, Cheng S, Mikol DD.

Cephalalgia. 2019 May 30:333102419854082. doi: 10.1177/0333102419854082. [Epub ahead of print]

PMID:
31146544
11.

James W. Lance MD.

Goadsby PJ.

Headache. 2019 Jun;59(6):825-827. doi: 10.1111/head.13552. No abstract available.

PMID:
31144299
12.

Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine.

Goadsby PJ, Wietecha LA, Dennehy EB, Kuca B, Case MG, Aurora SK, Gaul C.

Brain. 2019 May 27. pii: awz134. doi: 10.1093/brain/awz134. [Epub ahead of print]

13.

Marco Polo of Australian neurology.

Kiernan MC, Goadsby PJ, Burke D.

J Neurol Neurosurg Psychiatry. 2019 Jun;90(6):627-628. doi: 10.1136/jnnp-2019-320989. Epub 2019 May 2. No abstract available.

PMID:
31048340
14.

N-Methyl-d-aspartate receptor open-channel blockers memantine and magnesium modulate nociceptive trigeminovascular neurotransmission in rats.

Hoffmann J, Storer RJ, Park JW, Goadsby PJ.

Eur J Neurosci. 2019 Apr 22. doi: 10.1111/ejn.14423. [Epub ahead of print]

PMID:
31009120
15.

Onset of efficacy and duration of response of galcanezumab for the prevention of episodic migraine: a post-hoc analysis.

Goadsby PJ, Dodick DW, Martinez JM, Ferguson MB, Oakes TM, Zhang Q, Skljarevski V, Aurora SK.

J Neurol Neurosurg Psychiatry. 2019 Aug;90(8):939-944. doi: 10.1136/jnnp-2018-320242. Epub 2019 Apr 19.

16.

Efficacy and safety of erenumab (AMG334) in episodic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study.

Goadsby PJ, Paemeleire K, Broessner G, Brandes J, Klatt J, Zhang F, Picard H, Lenz R, Mikol DD.

Cephalalgia. 2019 Jun;39(7):817-826. doi: 10.1177/0333102419835459. Epub 2019 Apr 13.

PMID:
30982348
17.

The discovery and development of inhaled therapeutics for migraine.

Vandenbussche N, Goadsby PJ.

Expert Opin Drug Discov. 2019 Jun;14(6):591-599. doi: 10.1080/17460441.2019.1598373. Epub 2019 Mar 29.

PMID:
30924698
18.

Health state utilities associated with attributes of migraine preventive treatments based on patient and general population preferences.

Matza LS, Deger KA, Vo P, Maniyar F, Goadsby PJ.

Qual Life Res. 2019 Mar 28. doi: 10.1007/s11136-019-02163-3. [Epub ahead of print]

PMID:
30924071
19.

Dr James Lance, Professor of Neurology in Sydney, Australia, died on 20 February 2019, age 92.

Edvinsson L, Evers S, Goadsby PJ.

Cephalalgia. 2019 Apr;39(5):681-682. doi: 10.1177/0333102419840639. Epub 2019 Mar 21. No abstract available.

PMID:
30897943
20.

Author response: Gray matter volume modifications in migraine: A cross-sectional and longitudinal study.

Filippi M, Messina R, Goadsby PJ, Rocca MA.

Neurology. 2019 Mar 19;92(12):587-588. doi: 10.1212/WNL.0000000000007132. No abstract available.

PMID:
30886079
21.

Discovery of CGRP in relation to migraine.

Edvinsson L, Goadsby PJ.

Cephalalgia. 2019 Mar;39(3):331-332. doi: 10.1177/0333102418779544. No abstract available.

PMID:
30827155
22.

Guidelines of the International Headache Society for controlled trials of acute treatment of migraine attacks in adults: Fourth edition.

Diener HC, Tassorelli C, Dodick DW, Silberstein SD, Lipton RB, Ashina M, Becker WJ, Ferrari MD, Goadsby PJ, Pozo-Rosich P, Wang SJ, Mandrekar J; International Headache Society Clinical Trials Standing Committee.

Cephalalgia. 2019 May;39(6):687-710. doi: 10.1177/0333102419828967. Epub 2019 Feb 26.

23.

Teaching NeuroImages: Greater occipital nerve injection: A cautionary tale.

Wei DY, Connor S, Goadsby PJ.

Neurology. 2019 Feb 12;92(7):e746-e747. doi: 10.1212/WNL.0000000000006929. No abstract available.

PMID:
30745452
24.

Lorcaserin Safety in Overweight or Obese Patients.

Vandenbussche N, Goadsby PJ.

N Engl J Med. 2019 Jan 3;380(1):99. doi: 10.1056/NEJMc1813971. No abstract available.

PMID:
30601744
25.

Nitroglycerine triggers triptan-responsive cranial allodynia and trigeminal neuronal hypersensitivity.

Akerman S, Karsan N, Bose P, Hoffmann JR, Holland PR, Romero-Reyes M, Goadsby PJ.

Brain. 2019 Jan 1;142(1):103-119. doi: 10.1093/brain/awy313.

26.

Cortical abnormalities in episodic migraine: A multi-center 3T MRI study.

Magon S, May A, Stankewitz A, Goadsby PJ, Schankin C, Ashina M, Amin FM, Seifert CL, Mallar Chakravarty M, Müller J, Sprenger T.

Cephalalgia. 2019 Apr;39(5):665-673. doi: 10.1177/0333102418795163. Epub 2018 Dec 10.

PMID:
30525946
27.

Biological insights from the premonitory symptoms of migraine.

Karsan N, Goadsby PJ.

Nat Rev Neurol. 2018 Dec;14(12):699-710. doi: 10.1038/s41582-018-0098-4. Review.

PMID:
30448858
28.

Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study.

Detke HC, Goadsby PJ, Wang S, Friedman DI, Selzler KJ, Aurora SK.

Neurology. 2018 Dec 11;91(24):e2211-e2221. doi: 10.1212/WNL.0000000000006640. Epub 2018 Nov 16.

29.

Divergent influences of the locus coeruleus on migraine pathophysiology.

Vila-Pueyo M, Strother LC, Kefel M, Goadsby PJ, Holland PR.

Pain. 2019 Feb;160(2):385-394. doi: 10.1097/j.pain.0000000000001421.

30.

Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study.

Reuter U, Goadsby PJ, Lanteri-Minet M, Wen S, Hours-Zesiger P, Ferrari MD, Klatt J.

Lancet. 2018 Nov 24;392(10161):2280-2287. doi: 10.1016/S0140-6736(18)32534-0. Epub 2018 Oct 22.

PMID:
30360965
31.

Recommendations on the Use of Anti-CGRP Monoclonal Antibodies in Children and Adolescents.

Szperka CL, VanderPluym J, Orr SL, Oakley CB, Qubty W, Patniyot I, Lagman-Bartolome AM, Morris C, Gautreaux J, Victorio MC, Hagler S, Narula S, Candee MS, Cleves-Bayon C, Rao R, Fryer RH, Bicknese AR, Yonker M, Hershey AD, Powers SW, Goadsby PJ, Gelfand AA.

Headache. 2018 Nov;58(10):1658-1669. doi: 10.1111/head.13414. Epub 2018 Oct 15. No abstract available.

PMID:
30324723
32.

Prolonged migraine aura: new insights from a prospective diary-aided study.

Viana M, Sances G, Linde M, Nappi G, Khaliq F, Goadsby PJ, Tassorelli C.

J Headache Pain. 2018 Aug 31;19(1):77. doi: 10.1186/s10194-018-0910-y.

33.

The Migraine Postdrome.

Bose P, Karsan N, Goadsby PJ.

Continuum (Minneap Minn). 2018 Aug;24(4, Headache):1023-1031. doi: 10.1212/CON.0000000000000626.

PMID:
30074547
34.

The Migraine Premonitory Phase.

Karsan N, Bose P, Goadsby PJ.

Continuum (Minneap Minn). 2018 Aug;24(4, Headache):996-1008. doi: 10.1212/CON.0000000000000624.

PMID:
30074545
35.

Identifying Natural Subgroups of Migraine Based on Comorbidity and Concomitant Condition Profiles: Results of the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study.

Lipton RB, Fanning KM, Buse DC, Martin VT, Reed ML, Manack Adams A, Goadsby PJ.

Headache. 2018 Jul;58(7):933-947. doi: 10.1111/head.13342. Epub 2018 Jul 19.

PMID:
30024028
36.

Cluster Headache and Calcitonin Gene-Related Peptide-More on Quantum Therapeutics in Headache Medicine.

Gelfand AA, Goadsby PJ.

JAMA Neurol. 2018 Oct 1;75(10):1179-1180. doi: 10.1001/jamaneurol.2018.1428. No abstract available.

PMID:
29987331
37.

Recent advances in headache neuroimaging.

Messina R, Filippi M, Goadsby PJ.

Curr Opin Neurol. 2018 Aug;31(4):379-385. doi: 10.1097/WCO.0000000000000573. Review.

PMID:
29952833
38.

Gray matter volume modifications in migraine: A cross-sectional and longitudinal study.

Messina R, Rocca MA, Colombo B, Pagani E, Falini A, Goadsby PJ, Filippi M.

Neurology. 2018 Jul 17;91(3):e280-e292. doi: 10.1212/WNL.0000000000005819. Epub 2018 Jun 20.

PMID:
29925551
39.

Comment: Noninvasive neurostimulation for migraine should be part of the general neurologist's therapeutic armamentarium.

Lipton RB, Goadsby PJ.

Neurology. 2018 Jul 24;91(4):167. doi: 10.1212/WNL.0000000000005870. Epub 2018 Jun 15. No abstract available.

PMID:
29907607
40.

Emergence of Pituitary Adenoma in a Child during Surveillance: Clinical Challenges and the Family Members' View in an AIP Mutation-Positive Family.

Marques P, Barry S, Ronaldson A, Ogilvie A, Storr HL, Goadsby PJ, Powell M, Dang MN, Chahal HS, Evanson J, Kumar AV, Grieve J, Korbonits M.

Int J Endocrinol. 2018 Apr 4;2018:8581626. doi: 10.1155/2018/8581626. eCollection 2018.

41.

Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine: A Randomized Clinical Trial.

Dodick DW, Silberstein SD, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T, Grozinski-Wolff M, Yang R, Ma Y, Aycardi E.

JAMA. 2018 May 15;319(19):1999-2008. doi: 10.1001/jama.2018.4853.

42.

Overview of Trigeminal Autonomic Cephalalgias: Nosologic Evolution, Diagnosis, and Management.

Wei DY, Yuan Ong JJ, Goadsby PJ.

Ann Indian Acad Neurol. 2018 Apr;21(Suppl 1):S39-S44. doi: 10.4103/aian.AIAN_348_17. Review.

43.

Cluster Headache: Epidemiology, Pathophysiology, Clinical Features, and Diagnosis.

Wei DY, Yuan Ong JJ, Goadsby PJ.

Ann Indian Acad Neurol. 2018 Apr;21(Suppl 1):S3-S8. doi: 10.4103/aian.AIAN_349_17. Review.

44.

Migraine Therapy: Current Approaches and New Horizons.

Goadsby PJ, Holland PR.

Neurotherapeutics. 2018 Apr;15(2):271-273. doi: 10.1007/s13311-018-0626-3. No abstract available.

45.

CGRP - a target for acute therapy in migraine: Clinical data.

Messina R, Goadsby PJ.

Cephalalgia. 2019 Mar;39(3):420-427. doi: 10.1177/0333102418768095. Epub 2018 Apr 4.

PMID:
29616830
46.

Migraine is common in patients with sarcoidosis.

Gelfand JM, Gelfand AA, Goadsby PJ, Benn BS, Koth LL.

Cephalalgia. 2018 Dec;38(14):2079-2082. doi: 10.1177/0333102418768037. Epub 2018 Mar 26.

PMID:
29580067
47.

Targeted CGRP Small Molecule Antagonists for Acute Migraine Therapy.

Holland PR, Goadsby PJ.

Neurotherapeutics. 2018 Apr;15(2):304-312. doi: 10.1007/s13311-018-0617-4. Review.

48.

Transcranial Magnetic Stimulation for Migraine Prevention in Adolescents: A Pilot Open-Label Study.

Irwin SL, Qubty W, Allen IE, Patniyot I, Goadsby PJ, Gelfand AA.

Headache. 2018 May;58(5):724-731. doi: 10.1111/head.13284. Epub 2018 Mar 12.

PMID:
29528485
49.

Flunarizine in migraine-related headache prevention: results from 200 patients treated in the UK.

Karsan N, Palethorpe D, Rattanawong W, Marin JC, Bhola R, Goadsby PJ.

Eur J Neurol. 2018 Jun;25(6):811-817. doi: 10.1111/ene.13621. Epub 2018 Apr 11.

PMID:
29512871
50.

A multicenter, prospective, single arm, open label, observational study of sTMS for migraine prevention (ESPOUSE Study).

Starling AJ, Tepper SJ, Marmura MJ, Shamim EA, Robbins MS, Hindiyeh N, Charles AC, Goadsby PJ, Lipton RB, Silberstein SD, Gelfand AA, Chiacchierini RP, Dodick DW.

Cephalalgia. 2018 May;38(6):1038-1048. doi: 10.1177/0333102418762525. Epub 2018 Mar 4.

Supplemental Content

Loading ...
Support Center